Manatee County Biotech Firm Lakewood-Amedex Begins Trading on Nasdaq
A clinical-stage biotechnology company with roots in Manatee County has reached a major milestone after beginning to trade on the Nasdaq Capital Market. Lakewood-Amedex Biotherapeutics is now publicly listed under the ticker symbol LABT, marking a significant step forward in its growth and development.
Lakewood-Amedex Biotherapeutics focuses on developing innovative therapies designed to prevent and treat infectious diseases, particularly those involving antibiotic-resistant bacteria. The company’s research centers on antimicrobial peptides, which are engineered compounds intended to combat infections that are increasingly difficult to treat with traditional antibiotics.
The company has longstanding ties to Manatee County, where it has operated as part of the region’s growing life sciences and healthcare sector. Over the years, Lakewood-Amedex has advanced its clinical pipeline while maintaining a local presence that contributes to the area’s economic and scientific landscape.
Lakewood-Amedex originated from a merger between Lakewood Pharmaceuticals and Amedex Inc., combining resources and expertise to accelerate the development of its therapeutic candidates. Since then, the company has progressed through various stages of research and clinical planning, positioning itself within the competitive biotech industry.
Its transition to a publicly traded company provides increased access to capital markets, which can support ongoing research, clinical trials, and potential commercialization efforts. The Nasdaq Capital Market listing is often seen as an important platform for emerging growth companies seeking to expand visibility among investors and the broader healthcare sector.
As Lakewood-Amedex Biotherapeutics moves forward, its presence on Nasdaq highlights both the company’s progress and the role Manatee County continues to play in supporting innovation within the biotechnology field.